Search

Your search keyword '"Sarah W. M. Lee"' showing total 4 results
Start Over Author "Sarah W. M. Lee"
4 results on '"Sarah W. M. Lee"'

2. Compassionate Use of Ripretinib for Patients With Metastatic Gastrointestinal Stromal Tumors: Taiwan and Hong Kong Experience

Author

Li-Ching Lin, Wen-Kuan Huang, Chueh-Chuan Yen, Ching-Yao Yang, Meng-Ta Sung, Natalie S. M. Wong, Daniel T. T. Chua, Sarah W. M. Lee, Jen-Shi Chen, and Chun-Nan Yeh

Subjects
ripretinib, GIST, compassionate use, advanced, metastatic, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

BackgroundRipretinib was recently approved for the fourth-line targeted therapy for advanced gastrointestinal stromal tumor (GIST) refractory to imatinib, sunitinib, and regorafenib based on the pivotal INVICTUS phase III study. The INVICTUS study demonstrated significantly improved median progression-free survival (PFS) of 6.3 months and an overall survival (OS) insignificant benefit of ripretinib of 15.1 months as compared with placebo in 85 patients with advanced metastatic GIST. However, treatment outcome for the Chinese population, including in Taiwan and Hong Kong, was lacking.Material and MethodA compassionate study regarding ripretinib use for patients with advanced/metastatic GIST was conducted from March 2020 to March 2021 to assess the treatment efficacy and safety in Taiwan and Hong Kong patients.ResultTwenty evaluable patients (16 men and 4 women) with heavily pretreated metastatic GIST receiving ripretinib from March 2020 to March 2021 were enrolled to evaluate the treatment outcome. The response and clinical benefit rates to ripretinib were 25% (5/20) and 60% (12/20), respectively. The median PFS and OS in this compassionate cohort receiving ripretinib were 6.1 months and not reachable, respectively. Albumin less than 3.5 and disease progression after ripretinib use were the two independent unfavorable factors for PFS. There were 14 out of 20 (70%) experiencing any grade adverse event (AE). Loss of hair is the most common grade I to II AE with an incidence of 55%. Grade III AEs included diarrhea, skin rash, and anemia with one patient (5%) for each AE.ConclusionsLate-line ripretinib use in pretreated Taiwan and Hong Kong patients with advanced GIST showed efficacy consistent with the INVICTUS study. Albumin less than 3.5 and disease progression after ripretinib use were the two independent unfavorable factors for PFS. Ripretinib is generally tolerable, with loss of hair being the most common AE.

Published
2022
Full Text
View/download PDF

3. Prognostic nomogram for refining the prognostication of the proposed 8th edition of the AJCC/UICC staging system for nasopharyngeal cancer in the era of intensity-modulated radiotherapy

Author

Brian O'Sullivan, Lucy L.K. Chan, Sarah W. M. Lee, Christine M. Glastonbury, Randal S. Weber, You Ping Xiao, Jingfeng Zong, Yun Bin Chen, Shao Jun Lin, Henry C.K. Sze, Wai Tong Ng, Quynh-Thu Le, Qiao Juan Guo, Wai Kuen Kan, William M. Lydiatt, Horace C.W. Choi, A. Dimitrios Colevas, Anne W.M. Lee, Jatin P. Shah, Jianji Pan, and Wei Xu

Subjects
0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, business.industry, Nasopharyngeal neoplasm, Cancer, Retrospective cohort study, Nomogram, medicine.disease, Primary tumor, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, 030220 oncology & carcinogenesis, Internal medicine, Cohort, medicine, Stage (cooking), Nuclear medicine, business, Survival rate
Abstract

BACKGROUND The objective of this study was to develop a nomogram for refining prognostication for patients with nondisseminated nasopharyngeal cancer (NPC) staged with the proposed 8th edition of the American Joint Committee on Cancer (AJCC)/Union for International Cancer Control (UICC) staging system. METHODS Consecutive patients who had been investigated with magnetic resonance imaging, staged with the proposed 8th edition of the AJCC/UICC staging system, and irradiated with intensity-modulated radiotherapy from June 2005 to December 2010 were analyzed. A cohort of 1197 patients treated at Fujian Provincial Cancer Hospital was used as the training set, and the results were validated with 412 patients from Pamela Youde Nethersole Eastern Hospital. Cox regression analyses were performed to identify significant prognostic factors for developing a nomogram to predict overall survival (OS). The discriminative ability was assessed with the concordance index (c-index). A recursive partitioning algorithm was applied to the survival scores of the combined set to categorize the patients into 3 risk groups. RESULTS A multivariate analysis showed that age, gross primary tumor volume, and lactate dehydrogenase were independent prognostic factors for OS in addition to the stage group. The OS nomogram based on all these factors had a statistically higher bias-corrected c-index than prognostication based on the stage group alone (0.712 vs 0.622, P

Published
2016

4. Reirradiation with intensity-modulated radiotherapy for locally recurrent T3 to T4 nasopharyngeal carcinoma

Author

Lucy L.K. Chan, Anne W.M. Lee, Wai Man Hung, Sarah W. M. Lee, Michael C.H. Lee, Amy T.Y. Chang, Henry C.K. Sze, Wai Tong Ng, and Oscar S.H. Chan

Subjects
0301 basic medicine, Adult, Male, medicine.medical_specialty, medicine.medical_treatment, Locally advanced, Gross Target Volume, Kaplan-Meier Estimate, Risk Assessment, Disease-Free Survival, Re-Irradiation, Cohort Studies, 03 medical and health sciences, Temporal lobe necrosis, 0302 clinical medicine, Positron Emission Tomography Computed Tomography, medicine, Humans, In patient, Neoplasm Invasiveness, Aged, Neoplasm Staging, Proportional Hazards Models, Retrospective Studies, Analysis of Variance, Nasopharyngeal Carcinoma, business.industry, Carcinoma, Nasopharyngeal Neoplasms, Radiotherapy Dosage, Middle Aged, medicine.disease, Prognosis, Survival Analysis, Surgery, Radiation therapy, 030104 developmental biology, Logistic Models, Otorhinolaryngology, Nasopharyngeal carcinoma, 030220 oncology & carcinogenesis, Recurrent Nasopharyngeal Carcinoma, Female, Radiology, Intensity modulated radiotherapy, Radiotherapy, Intensity-Modulated, Neoplasm Recurrence, Local, business
Abstract

Background The purpose of this study was to assess the efficacy and toxicities of reirradiation using intensity-modulated radiotherapy (IMRT) in patients with locally advanced recurrent nasopharyngeal carcinoma (NPC). Methods Thirty-eight patients with consecutive rT3 to rT4 NPC treated between 2005 and 2013 were retrospectively analyzed. Results The 3-year overall survival (OS), progression-free survival (PFS), and local control rate were 47.2%, 17.5%, and 44.3%, respectively. Gross target volume (GTV) D95, GTV D50, and age were all important prognostic factors for OS and PFS, but only GTV D95 was an important determinant for local control. A total of 73.7% patients experienced ≥1 grade 3 late toxicities and 3 patients died of massive epistaxis. Temporal lobe necrosis (TLN) developed sooner with a higher total biological equivalent dose. Conclusion Adequate tumor dose coverage was important for treating rT3 to rT4 NPC. Although late complications were common, treatment-related mortality was solely vascular in nature. Dose constraints of neurologic structures for reirradiation should be revised with the latest information on late toxicities. © 2016 Wiley Periodicals, Inc. Head Neck, 2016

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results